Rapid remission of treatment-resistant ankylosing spondylitis with etanercept?a drug for refractory ankylosing spondylitis?

Reintroduction of etanercept during trea

Reintroduction of etanercept during treatment of cutaneousMycobacterium marinuminfection in a patient with ankylosing spondylitis

✍ Dare, Jason A. ;Jahan, Shormi ;Hiatt, Kim ;Torralba, Karina D. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

Six-month results of a double-blind, pla

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

✍ J. Brandt; A. Khariouzov; J. Listing; H. Haibel; H. Sörensen; L. Grassnickel; M. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## Objective There is increasing evidence that tumor necrosis factor α (TNFα) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFα therapy with etanercept, a 75‐kd recepto

Switching from infliximab to once-weekly

Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four–week study

✍ Cantini, Fabrizio ;Niccoli, Laura ;Benucci, Maurizio ;Chindamo, Daniela ;Nannini 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views

A six-month randomized, controlled, doub

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis

✍ Walter P. Maksymowych; Gian S. Jhangri; Avril A. Fitzgerald; Sharon LeClercq; Pe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Abstract ## Objective To determine the safety and efficacy of intravenous (IV) pamidronate treatment in ankylosing spondylitis (AS) patients who have had a suboptimal response to nonsteroidal antiinflammatory drugs (NSAIDs). ## Methods Pamidronate at 60 mg was compared with pamidronate at 10

Efficacy of celecoxib, a cyclooxygenase

Efficacy of celecoxib, a cyclooxygenase 2–specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

✍ Maxime Dougados; Jehan-Michel Béhier; Irène Jolchine; Andrei Calin; Désirée van 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

A six-month randomized, controlled, doub

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis: Comment on the article by Maksymowych et al

✍ Ranju Singh; Yamini Menon; Raquel Cuchacovich; Luis R. Espinoza 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views